Krakatoa Resources Ltd (ASX: KTA) has completed more than 1,000 metres of diamond drilling and underground core sampling at the Zopkhito Antimony-Gold Project in Georgia so far this year, as work accelerates towards a maiden JORC-compliant mineral resource estimate.
Surface drilling has shifted from the eastern part of the system to the West Zone, targeting previously undrilled veins that account for a significant portion of the project's historical foreign resource estimate.
Critical Resources Ltd (ASX:CRR) has joined forces with Australia’s national science agency CSIRO to optimise and scale its Dry Supersonic Deposition (DSD) battery manufacturing technology, adding an Australian research workstream to its existing development program in the United States.
The collaborative research project will be co-funded through CSIRO’s Kick-Start program and will focus on refining CRR’s solvent- and binder-free DSD process, which forms part of the company’s licensable battery manufacturing intellectual property.
Gelion PLC (AIM:GELN, OTC:GELNF, FRA:X0S), the sulfur battery technology company, has completed a government-backed programme in which its cathode material passed independent drone mission testing carried out by QinetiQ Group PLC (LSE:QQ.).
The cells, built and evaluated by the UK defence, security and aerospace company, completed simulated drone flight profiles including repeated high-power take-off and landing events.
Australian inflation eased only marginally in July, with headline consumer prices rising 3.5% over the year, down from 3.8% in June but above economists’ expectations for a sharper slowdown.
More importantly for the Reserve Bank of Australia (RBA), trimmed mean inflation — its preferred measure of underlying price pressures — held steady at 3.6% over the 12 months to July, remaining well above the central bank’s 2%-3% target range.
D3 Energy Ltd (ASX:D3E, OTCQX:DNRGF) has initiated a high-resolution 2D seismic survey at its Nooitgedacht project in South Africa.
The program aims to refine the geological model and support future well targeting across its flagship ER315 permit.
Ora Banda Mining Ltd (ASX:OBM, OTC:ESGFF) has delivered record revenue, production and cash generation for the year to June 30, 2026, as the ramp-up of its second underground mine, Sand King, transformed the group's operating performance.
Revenue doubled to $807.5 million from $404.3 million, while earnings before interest, tax, depreciation and amortisation (EBITDA) climbed 134% to $431.1 million.
Bitcoin has slipped back below US$79,000 after its rapid recovery ran into resistance above US$81,000, leaving traders to assess whether the latest surge marks the start of a more sustained crypto recovery or has simply moved too far too quickly.
At the latest check, Bitcoin was trading around US$78,800, while Ether was near US$2,460, Solana around US$97 and XRP close to US$1.45.
Entropy Neurodynamics Ltd (ASX:ENP, OTC:TYPTF) has secured a pre-clinical trial agreement with the University of California, San Francisco (UCSF) for a proposed US Phase 2 study comparing its precision-controlled psychedelic therapy TRP-8803 directly with widely prescribed antidepressant escitalopram.
The head-to-head trial is planned to enrol up to 80 young adults with Major Depressive Disorder (MDD) and is expected to begin in the first half of 2027, subject to US Food and Drug Administration (FDA) regulatory clearance.
FireFly Metals Ltd (ASX:FFM, TSX:FFM, OTC:FFMFF) has secured commitments for a A$180 million institutional equity raising and plans a further A$10 million share purchase plan (SPP), providing up to A$190 million to accelerate development and resource growth at its Green Bay Copper-Gold Project in Newfoundland, Canada.
The money will be used for early project works, procurement of long-lead equipment, technical studies and an extensive drilling program as FireFly works towards a final investment decision by mid-2027.
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has entered the new financial year with a significantly expanded US opportunity for its FebriDx rapid diagnostic test after securing regulatory, reimbursement and distribution milestones during the 12 months to June 30, 2026.
Revenue for the year rose 6% to US$13.2 million, with FebriDx revenue surging 875%, while gross profit reached US$7.9 million at a margin of 60.1%.
Nvidia Corp (NASDAQ:NVDA, XETRA:NVD) will put the strength of the artificial intelligence spending boom back under the microscope when the chip giant reports quarterly earnings after the US market closes on Wednesday.
The company is due to release results for the quarter ended July 26 at around 1.20 pm Pacific Time, followed by an analyst call at 2pm.
Prescient Therapeutics Ltd (ASX:PTX) has opened its share purchase plan (SPP) targeting up to $7 million to help advance its lead cancer therapy PTX-100 through its ongoing Phase 2a clinical program.
Eligible shareholders can subscribe for up to $30,000 of new shares at $0.065 each, representing an 18.8% discount to the 10-day volume-weighted average price and a 9.7% discount to the closing price on 24 August 2026.